Your session is about to expire
← Back to Search
Proton Pump Inhibitor
Secretol for Indigestion
Phase 1 & 2
Waitlist Available
Led By Ronnie Fass, MD
Research Sponsored by Effexus Pharmaceutical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 weeks of treatment
Awards & highlights
No Placebo-Only Group
All Individual Drugs Already Approved
Approved for 10 Other Conditions
Summary
This trial is evaluating two medications, Secretol and Nexium, to determine which is more effective at healing the esophagus and controlling symptoms in patients with esophagus damage and acid reflux. Both medications work by reducing stomach acid.
Eligible Conditions
- Indigestion
- Heartburn
- Acid Reflux
- Nausea, Vomiting, Heartburn
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 weeks of treatment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 weeks of treatment
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Primary objective is to evaluate the relationship between healing and study drug allotment.
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
Trial Design
2Treatment groups
Active Control
Group I: SecretolActive Control1 Intervention
Comparing the efficacy of 80/80 Secretol once daily in healing erosive esophagitis.
Group II: NexiumActive Control1 Intervention
Comparing 40 mg.once daily in healing erosive esophagitis.
Find a Location
Who is running the clinical trial?
Southern Arizona VA Health Care SystemFED
10 Previous Clinical Trials
868 Total Patients Enrolled
Effexus PharmaceuticalLead Sponsor
2 Previous Clinical Trials
18 Total Patients Enrolled
Ronnie Fass, MDPrincipal InvestigatorSouthern Arizona VA Health Care System
10 Previous Clinical Trials
379 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger